Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 1,201 in Gilead Sciences

  1. Advocates Adapt Global HIV Strategy for Cheaper HCV DrugsRead the original story w/Photo

    4 hrs ago | POZ

    ... to get cheaper, generic versions of HCV drugs onto international markets by pressuring manufacturers like Gilead Sciences to allow other companies to make them. Gilead's hep C drug Sovaldi (sofosbuvir) costs $1,000 a pill or $84,000 for a full ...

    Comment?

  2. Market Is Looking For Positive News - Cramer's Mad MoneyRead the original story w/Photo

    6 hrs ago | Seeking Alpha

    ... prices, especially in any oil-importing country, will put a lot of money in consumers' pockets," said Cote. Gilead Sciences (NASDAQ: GILD ) trades at just 12 times earnings and it has been stable above $100. Cramer thinks it is one of the best ...

    Comment?

  3. Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for SuccessRead the original story

    9 hrs ago | Business Wire

    All biotech companies - Gilead , Amgen , Biogen Idec and Celgene , in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need.

    Comment?

  4. CohBar, Inc. Announces Publication Of Preclinical...Read the original story

    Yesterday | BioSpace

    ... Kenneth Cundy, former Chief Scientific Officer at Xenoport, Inc. and Senior Director of Biopharmaceutics at Gilead Sciences, Inc. About CohBar CohBar (TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics ...

    Comment?

  5. NASDAQ Reaches A New Level Despite Several Negative ForcesRead the original story

    Yesterday | GuruFocus.com

    ... such as electric car manufacturers Tesla ( TSLA ), coffee chain Starbucks ( SBUX ) and biotech bigwig Gilead Sciences ( GILD ), to name a few. The growth in the tech-fired index has been brought about through carefully planned earnings growth and ...

    Comment?

  6. I'm Staying Long On Amgen, But Not Buying SharesRead the original story w/Photo

    Yesterday | Seeking Alpha

    The company has multiple shots on goal in the pipeline and the stock price is creating a base at these levels. Amgen is a company I purchased back in the May of 2013, when I believed it was a deeply undervalued biotech and it has been performing very well with a return of 49.71% versus the 26.41% gain the S&P 500 has posted.

    Comment?

  7. CVS Health Wins Over Analysts As Significant Growth Expected In The Next 5 YearsRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... of specialty drugs that charge its patients less cost. In this regard, the company has started offering Gilead Sciences' (NASDAQ: GILD ) Hepatitis C drugs Harvoni and Solvadi to customers who are on its Commercial, Exchange, Medicaid and Medicare ...

    Comment?

  8. France's Genfit Said to Mull Sale Amid Health-Care Deal BoomRead the original story

    Yesterday | The Washington Post

    ... Genfit faces competition from biotechnology companies such as Intercept Pharmaceuticals Inc. and Gilead Sciences Inc., which are racing to develop treatments for NASH. Large drugmakers are on the prowl for acquisitions to bolster their drug ...

    Comment?

  9. Publicly Funded InequalityRead the original story w/Photo

    Yesterday | Project Syndicate

    ... Jeffrey Sachs , is Sovaldi, a drug used to cure hepatitis C. As Sachs explains, the company that sells it, Gilead Sciences, holds a patent for the treatment that will not expire until 2028. As a result, Gilead can charge monopoly prices: $84,000 for ...

    Comment?

  10. False release hits trades involving Halifax firmRead the original story w/Photo

    Tuesday | The Chronicle Herald

    ... issued by the vaccine developer, announced that the firm had entered into a co-development agreement with Gilead Sciences Inc. of California and received fast-track approval from the United States Food and Drug Administration for clinical trials of ...

    Comment?

  11. Gilead Sciences' (GILD) Management Presents at Cowen & Company 35th...Read the original story w/Photo

    Tuesday | Seeking Alpha

    Good morning and welcome once again to Cowen & Company's 35th Annual Healthcare Conference. I am Phil Nadeau, a Biotech Analyst here at Cowen and it's my pleasure to introduce the next presenting company, Gilead.

    Comment?

  12. Gilead Sciences, Inc. v. Lee (Fed. Cir. 2015) - Filing of IDS after...Read the original story w/Photo

    Tuesday | jdsupra.com

    Gilead Sciences, Inc. v. Lee - Filing of IDS after Response to Restriction Requirement Constitutes Failure to Engage in Reasonable Efforts to Conclude Prosecution Last week, in Gilead Sciences, Inc. v.

    Comment?

  13. CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle...Read the original story

    Tuesday | Freshnews

    ... Kenneth Cundy, former Chief Scientific Officer at Xenoport, Inc. and Senior Director of Biopharmaceutics at Gilead Sciences, Inc. CohBar (TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics (MBTs), a new ...

    Comment?

  14. Federal Circuit Upholds Patent Term Adjustment Deduction for IDS Filed After Restriction RequirementRead the original story w/Photo

    Tuesday | jdsupra.com

    In Gilead Sciences, Inc. v. Lee , the Federal Circuit upheld the USPTO's interpretation of the Patent Term Adjustment statute as permitting the USPTO to charge "Applicant Delay" when an Information Disclosure Statement is filed after a response to a Restriction Requirement has been filed.

    Comment?

  15. PrEP access for HIV prevention in Australia a step closer as Gilead applies to TGARead the original story w/Photo

    Monday | Sydney Star Observer

    Widespread, affordable access to PrEP as a HIV prevention in Australia is a step closer, with pharmaceutical company Gilead applying to the TGA to have it approved. US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Monday | Business Wire

    ... safety, pharmacovigilance, medical affairs, and regulatory operations. Its international team ... )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 35th Annual Health ...

    Comment?

  17. Juno Therapeutics Inc (JUNO), Avalanche Biotechnologies Inc (AAVL),...Read the original story w/Photo

    Monday | Insider Monkey

    ... by supporting publicly traded equities such as Apple Inc (NASDAQ:AAPL), Intel Corporation (NASDAQ:INTC), and Gilead Sciences, Inc. (NASDAQ:GILD). Juno Therapeutics Inc (NASDAQ:JUNO) was VHCP Management's top pick at the end of the last quarter, ...

    Comment?

  18. Gilead Sciences to Present at the Cowen and Company 35th Annual...Read the original story

    Monday Mar 2 | Freshnews

    Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Cowen and Company 35th Annual Health Care Conference in Boston. Paul Carter, Gilead's Executive Vice President, Commercial Operations, will provide an overview of the company at the conference on Tuesday, March 3 at 9:20 a.m. Eastern Time.

    Comment?

  19. Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals...Read the original story w/Photo

    Monday Mar 2 | Insider Monkey

    Jeremy Green 's Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February. The hedge fund is particularly bullish regarding its freshly acquired stake in Gilead Sciences, Inc. , which amounts to 368,600 shares.

    Comment?

  20. Bristol Myers' HCV Cocktail Has Gilead, AbbVie In Its CrosshairsRead the original story w/Photo

    Monday Mar 2 | Seeking Alpha

    ... evaluating a once-daily regimen of Bristol-Myers Squibb's NS5A inhibitor, daclatasvir, in combination with Gilead Sciences' Sovaldi (sofosbuvir) in patients co-infected with HCV and HIV achieved a 97% cure rate (n=149/153) as defined by SVR12 ...

    Comment?